Pharma wins reduction in data requirements for EU EVMPD product database
This article was originally published in SRA
Executive Summary
Following strong lobbying by the pharmaceutical industry, the European Medicines Agency has substantially reduced the amount of information that companies must provide by 2 July on all the products they market in the EU1,2. Industry will be relieved at the move, having pushed hard for a delay to the deadline or at least a reduction in the scope of the requirement.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.